CEFOPERAZONE\SULBACTAM: 797 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
797
Total FAERS Reports
131 (16.4%)
Deaths Reported
367
Hospitalizations
797
As Primary/Secondary Suspect
115
Life-Threatening
37
Disabilities
Active Ingredient: CEFOPERAZONE SODIUM\SULBACTAM SODIUM ·
First Report: 20030918 · Latest Report: 20250730
What Are the Most Common CEFOPERAZONE\SULBACTAM Side Effects?
#1 Most Reported
Off label use
155 reports (19.4%)
#2 Most Reported
Drug ineffective
88 reports (11.0%)
#3 Most Reported
Coagulopathy
62 reports (7.8%)
All CEFOPERAZONE\SULBACTAM Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 155 | 19.5% | 20 | 65 |
| Drug ineffective | 88 | 11.0% | 42 | 38 |
| Coagulopathy | 62 | 7.8% | 4 | 40 |
| Platelet count decreased | 59 | 7.4% | 3 | 23 |
| Hepatic function abnormal | 57 | 7.2% | 4 | 10 |
| Drug-induced liver injury | 39 | 4.9% | 3 | 14 |
| Condition aggravated | 38 | 4.8% | 7 | 20 |
| Pyrexia | 34 | 4.3% | 5 | 21 |
| Diarrhoea | 32 | 4.0% | 3 | 19 |
| Pruritus | 31 | 3.9% | 0 | 12 |
| Rash | 27 | 3.4% | 2 | 10 |
| Product use in unapproved indication | 25 | 3.1% | 2 | 9 |
| Dyspnoea | 24 | 3.0% | 1 | 18 |
| Pathogen resistance | 24 | 3.0% | 10 | 15 |
| Haemoglobin decreased | 23 | 2.9% | 1 | 11 |
| Hepatic enzyme increased | 22 | 2.8% | 1 | 6 |
| Klebsiella infection | 22 | 2.8% | 9 | 15 |
| Pneumonia | 22 | 2.8% | 8 | 14 |
| Liver injury | 20 | 2.5% | 2 | 5 |
| Prothrombin time prolonged | 19 | 2.4% | 2 | 8 |
Who Reports CEFOPERAZONE\SULBACTAM Side Effects? Age & Gender Data
Gender: 30.6% female, 69.4% male. Average age: 57.9 years. Most reports from: CN. View detailed demographics →
Is CEFOPERAZONE\SULBACTAM Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 0 |
| 2007 | 6 | 4 | 2 |
| 2012 | 2 | 0 | 1 |
| 2014 | 6 | 1 | 2 |
| 2015 | 23 | 1 | 11 |
| 2016 | 24 | 7 | 12 |
| 2017 | 30 | 6 | 13 |
| 2018 | 34 | 2 | 13 |
| 2019 | 59 | 7 | 22 |
| 2020 | 55 | 0 | 20 |
| 2021 | 80 | 5 | 32 |
| 2022 | 40 | 2 | 13 |
| 2023 | 84 | 3 | 37 |
| 2024 | 49 | 1 | 23 |
| 2025 | 36 | 3 | 21 |
What Is CEFOPERAZONE\SULBACTAM Used For?
| Indication | Reports |
|---|---|
| Pneumonia | 153 |
| Anti-infective therapy | 106 |
| Infection | 87 |
| Antibiotic therapy | 52 |
| Product used for unknown indication | 40 |
| Lung infection | 37 |
| Covid-19 | 24 |
| Pyrexia | 19 |
| Klebsiella infection | 17 |
| Sepsis | 16 |
CEFOPERAZONE\SULBACTAM vs Alternatives: Which Is Safer?
CEFOPERAZONE\SULBACTAM vs CEFOTAXIME
CEFOPERAZONE\SULBACTAM vs CEFOXITIN
CEFOPERAZONE\SULBACTAM vs CEFPODOXIME
CEFOPERAZONE\SULBACTAM vs CEFPODOXIME PROXETIL
CEFOPERAZONE\SULBACTAM vs CEFPROZIL
CEFOPERAZONE\SULBACTAM vs CEFTAROLINE
CEFOPERAZONE\SULBACTAM vs CEFTAROLINE FOSAMIL
CEFOPERAZONE\SULBACTAM vs CEFTAZIDIME
CEFOPERAZONE\SULBACTAM vs CEFTIBUTEN
CEFOPERAZONE\SULBACTAM vs CEFTOLOZANE\TAZOBACTAM
Official FDA Label for CEFOPERAZONE\SULBACTAM
Official prescribing information from the FDA-approved drug label.